PIC North America News and Activities

PIC North America is owned by Genus.

Genus is one of the...

• FTSE 350;
• TOB Iconic 10,000.

Genus is a company listed under the stock ticker GNS (GB).

Genus has a direct presence in 10 countries.

Genus has 10 subsidiaries including ABS Africa, ABS Australia and ABS Canada.

They are in:

• Farming73%
• Biotechnology27%

View the org chart displaying its 20 main executives

Most searched biographies at PIC North America

• Matt Biancheri, Director and Head of Global Finance
• Matt Culbertson, Chief Operating Officer
• David Casey, Senior Director, Product Performance, Europe and Asia

Popular executive movements at PIC North America

• Amanda Szumutku, Human Resources Business Partner, has left the company  (posted on April 9 2026).

Popular executive movements at Genus

• Celia Baxter will join the company as Non-Executive Director on Jan. 1, 2026  (posted on November 19 2025).

Create your alert
to follow the executive moves at PIC North America.

Genus has 2,411 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Obsidian Therapeutics has filed its IPO. Its stock ticker will be OBX. (posted on June 18 2026).
• PharmaEssentia has acquired Forus Therapeutics (posted on June 18 2026).
• Biogen has announced the acquisition of RayThera  (posted on June 18 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Carl Gordon - Director at Odyssey Therapeutics

Learn more about the Biotechnology industry

Press releases by PIC North America

Social media about PIC North America

• PIC North America on Wikipedia, Google News & Yahoo Finance
• PIC North America on LinkedIn, X (Twitter) & YouTube